VistaGen Therapeutics Newsroom

VistaGen Therapeutics Advances Neurocircuitry Treatments

TipRanksDec 7 06:18

Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12

Futu NewsNov 21 21:31 · Ratings

Vistagen to Present at the Stifel 2024 Healthcare Conference

BusinesswireNov 14 21:30

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript Summary

Futu NewsNov 10 21:04 · Conference Call

VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating

TipRanksNov 9 23:35 · Ratings

Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12

Futu NewsNov 9 23:32 · Ratings

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges With a ...

Yahoo FinanceNov 8 15:31

Vistagen Therapeutics Reports Increased R&D Expenses

TipRanksNov 8 13:43

VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

SECNov 8 11:38

VistaGen Therapeutics GAAP EPS of -$0.42 Misses by $0.03, Revenue of $0.18M Beats by $0.15M

Seeking AlphaNov 8 06:16

VistaGen Therapeutics | 10-Q: Q2 2025 Earnings Report

SECNov 8 05:38 · Announcements

Express News | Vistagen Therapeutics Inc - Qtrly Shr Loss $0.42

BreakingsNov 8 05:31

Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $183M

MT NewswiresNov 8 05:20

Earnings Preview: VTGN to Report Financial Results Post-market on November 07

$VistaGen Therapeutics(VTGN.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $VistaGen Therapeutics(VTGN.US)$ to post revenue of USD3

Futu NewsNov 1 22:45

Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Dow JonesNov 1 20:31

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

BusinesswireOct 9 20:30

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

Yahoo FinanceSep 7 00:00

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

Yahoo FinanceSep 5 22:14

Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12

Maxim Group analyst Jason McCarthy maintains $VistaGen Therapeutics(VTGN.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.

Futu NewsAug 15 20:31 · Ratings

Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials

TipRanksAug 15 19:46 · Ratings